NIH, FDA seek lessons from hepatitis B drug trial deaths.
Macilwain
C
C
D000998:Antiviral Agents / Q000009:adverse effects*; D001086:Arabinofuranosyluracil / Q000009:adverse effects / Q000031:analogs & derivatives*; D006509:Hepatitis B / Q000188:drug therapy*; D006801:Humans; D009316:National Institutes of Health (U.S.); D014481:United States; D014486:United States Food and Drug Administration
D000998:Antiviral Agents; D001086:Arabinofuranosyluracil; C043457:fialuridine